These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11977703)

  • 1. Prevention of pneumococcal disease in young children.
    Steimle D; Aston R; Van Damme P
    Nurs Stand; 2001 Oct 3-9; 16(3):42-4. PubMed ID: 11977703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive pneumococcal disease in England and Wales: vaccination implications.
    Sleeman K; Knox K; George R; Miller E; Waight P; Griffiths D; Efstratiou A; Broughton K; Mayon-White RT; Moxon ER; Crook DW; ;
    J Infect Dis; 2001 Jan; 183(2):239-246. PubMed ID: 11120930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of pneumococcal disease through vaccination.
    Gentile A; Bazán V
    Vaccine; 2011 Sep; 29 Suppl 3():C15-25. PubMed ID: 21896348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
    Miller E; Andrews NJ; Waight PA; Slack MP; George RC
    Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of pneumococcal polysaccharide vaccine in at-risk populations in England and Wales 1999-2005.
    Pebody RG; Hippisley-Cox J; Harcourt S; Pringle M; Painter M; Smith G
    Epidemiol Infect; 2008 Mar; 136(3):360-9. PubMed ID: 17445314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.
    Andrews NJ; Waight PA; George RC; Slack MP; Miller E
    Vaccine; 2012 Nov; 30(48):6802-8. PubMed ID: 23000122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2013 Mar; 56(5):633-40. PubMed ID: 23175560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current burden of pneumococcal disease in England and Wales.
    Melegaro A; Edmunds WJ; Pebody R; Miller E; George R
    J Infect; 2006 Jan; 52(1):37-48. PubMed ID: 16368459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal conjugate vaccine for young children.
    Selman S; Hayes D; Perin LA; Hayes WS
    Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic resistance in Latin America: a cause for alarm.
    Valenzuela MT; de Quadros C
    Vaccine; 2009 Aug; 27 Suppl 3():C25-8. PubMed ID: 19540634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
    Whitney CG; Farley MM; Hadler J; Harrison LH; Bennett NM; Lynfield R; Reingold A; Cieslak PR; Pilishvili T; Jackson D; Facklam RR; Jorgensen JH; Schuchat A;
    N Engl J Med; 2003 May; 348(18):1737-46. PubMed ID: 12724479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales.
    Flasche S; Slack M; Miller E
    Euro Surveill; 2011 May; 16(20):19868. PubMed ID: 21616047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.
    Adamkiewicz TV; Sarnaik S; Buchanan GR; Iyer RV; Miller ST; Pegelow CH; Rogers ZR; Vichinsky E; Elliott J; Facklam RR; O'Brien KL; Schwartz B; Van Beneden CA; Cannon MJ; Eckman JR; Keyserling H; Sullivan K; Wong WY; Wang WC
    J Pediatr; 2003 Oct; 143(4):438-44. PubMed ID: 14571216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal vaccines: World Health Organization position paper.
    Can Commun Dis Rep; 1999 Sep; 25(17):150-1. PubMed ID: 10513118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health.
    Kyaw MH; Jones IG; Campbell H
    Acta Paediatr; 2001 May; 90(5):473-6. PubMed ID: 11430703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Streptococcus pneumoniae-related illnesses in young children: secular trends and regional variation.
    Poehling KA; Szilagyi PG; Edwards K; Mitchel E; Barth R; Hughes H; Lafleur B; Schaffer SJ; Schwartz B; Griffin MR
    Pediatr Infect Dis J; 2003 May; 22(5):413-8. PubMed ID: 12792380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines.
    Lynch JP; Zhanel GG
    Curr Opin Pulm Med; 2010 May; 16(3):217-25. PubMed ID: 20375783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.